Special ArticleCanadian Cardiovascular Society position statement – Recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular diseaseDocument de principes de la Société canadienne de cardiologie : Recommandations pour diagnostiquer et traiter la dyslipidémie et prévenir la maladie cardiovasculaire
References (138)
- et al.
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial
Lancet
(2003) - et al.
Lifetime risk of developing coronary heart disease
Lancet
(1999) - et al.
Framingham risk score and prediction of lifetime risk for coronary heart disease
Am J Cardiol
(2004) - et al.
The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease
Am J Kidney Dis
(2004) - et al.
Carotid artery atherosclerosis in type-2 diabetic and nondiabetic subjects with and without symptomatic coronary artery disease (The Insulin Resistance Atherosclerosis Study)
Am J Cardiol
(2000) - et al.
Women with a low Framingham risk score and a family history of premature coronary heart disease have a high prevalence of subclinical coronary atherosclerosis
Am Heart J
(2005) - et al.
Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: The Study of Health Assessment and Risk in Ethnic groups (SHARE)
Lancet
(2000) - et al.
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study
Lancet
(2004) - et al.
Relation of family history of premature coronary heart disease and metabolic risk factors to risk of coronary arterial calcium in asymptomatic subjects
Am J Cardiol
(2005) - et al.
Maximal exercise test as a predictor of risk for mortality from coronary heart disease in asymptomatic men
Am J Cardiol
(2000)
Impact of minor electrocardiographic ST-segment and/or T-wave abnormalities on cardiovascular mortality during long-term follow-up
Am J Cardiol
(2003)
Lipoprotein(a) interactions with lipid and non-lipid risk factors in patients with early onset coronary artery disease: Results from the NHLBI Family Heart Study
Atherosclerosis
(1998)
Prognostic value of exercise electrocardiogram in men at high risk of future coronary heart disease: Multiple Risk Factor Intervention Trial experience
J Am Coll Cardiol
(1986)
Multislice spiral computed tomographic angiography of coronary arteries in patients with suspected coronary artery disease: An effective filter before catheter angiography?
Am Heart J
(2005)
Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men
Lancet
(1981)
Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: Summary of the 2003 update
CMAJ
(2003)
Intensive lipid lowering with atorvastatin in patients with stable coronary disease
N Engl J Med
(2005)
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial
JAMA
(2005)
Intensive versus moderate lipid lowering with statins after acute coronary syndromes
N Engl J Med
(2004)
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
Circulation
(2004)
The recent decline in mortality from coronary heart disease, 1980–1990. The effect of secular trends in risk factors and treatment
JAMA
(1997)
Modelling the decline in coronary heart disease deaths in England and Wales, 1981–2000: Comparing contributions from primary prevention and secondary prevention
BMJ
(2005)
Long-term trends in the incidence of and survival with heart failure
N Engl J Med
(2002)
Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)
Circulation
(2005)
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
N Engl J Med
(1995)
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial – Lipid-Lowering Arm (ASCOT-LLA)
Diabetes Care
(2005)
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
JAMA
(1998)
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)
JAMA
(2001)
The analysis by Manuel and colleagues creates controversy with headlines, not data
CMAJ
(2005)
Lipid screening to prevent coronary artery disease: A quantitative evaluation of evolving guidelines
CMAJ
(2000)
The 2003 Canadian recommendations for dyslipidemia management: Revisions are needed
CMAJ
(2005)
Major risk factors as antecedents of fatal and nonfatal coronary heart disease events
JAMA
(2003)
Prevalence of conventional risk factors in patients with coronary heart disease
JAMA
(2003)
Lifetime risk of coronary heart disease by cholesterol levels at selected ages
Arch Intern Med
(2003)
Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age
Circulation
(2006)
Prognostic significance of dyspnea in patients referred for cardiac stress testing
N Engl J Med
(2005)
Erectile dysfunction and subsequent cardiovascular disease
JAMA
(2005)
American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention
Circulation
(2003)
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
N Engl J Med
(2004)
Hospitalizations for coronary artery. disease among patients with systemic lupus erythematosus
Arthritis. Rheum
(2003)
Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study
Circulation
(2002)
Third Joint Force of European and other Societies on Cardiovascular Disease and Prevention in Clinical Practice European guidelines on cardiovascular disease and prevention in clinical practice
Atherosclerosis
(2003)
Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study
Circulation
(1996)
Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men Prospective results from the Quebec Cardiovascular Study
Circulation
(1997)
Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease
JAMA
(1998)
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
N Engl J Med
(1998)
Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes
Diabetes Care
(2002)
NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older
Diabetes
(2003)
The UKPDS risk engine: A model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
Clin Sci (Lond)
(2001)
Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: Results from a United Kingdom study
Diabet Med
(2005)
Cited by (0)
Copyright © 2006 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.